Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech are expanding their joint venture, Ai-nova Acquisition Corp (AAC), across Latin America following Ainnova's participation in the 2025 Healthcare Innovation Summit in Mexico City. The expansion includes commercial pilots in Chile and Dominican Republic hospitals, focusing on demonstrating cost reduction in preventive diagnostics and improved healthcare efficiency.

The pilots utilize Ainnova's Vision AI platform for real-time health risk identification, enabling specialty care referrals. The joint venture plans to deploy an automated retinal imaging device integrated with AI to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images and basic health data.

AAC holds global licensing rights for Ainnova's technology portfolio. The companies are pursuing regulatory approvals in Brazil through MDSAP certification for ANVISA requirements, while simultaneously preparing for FDA clinical trials in the United States.

Positive

• Global expansion into new markets (Chile, Dominican Republic, Brazil, US)
• Proprietary AI technology for multiple disease detection
• Strategic positioning in markets with existing reimbursement codes
• Global licensing rights secured through joint venture

Negative

• Pending regulatory approvals in major markets (FDA, ANVISA)
• Commercial pilots still in early stages
• Technology effectiveness not yet proven in clinical trials

LAS VEGAS, April 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that following Ainnova's sponsorship and its CEO's key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova's strong presence in Mexico by expanding its footprint across Latin America.  

Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care—from primary to highly specialized services.  These pilot programs aim to demonstrate, (i) cost reduction in preventive diagnostics; (ii) increased efficiency in medical resource allocation and patient flow; (iii) enhanced institutional reputation driven by technological innovation; and (iv) improved profitability for participating healthcare centers through optimized patient referrals.

The pilot programs leverage Ainnova's proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected.  The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening.  From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.

Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova's technology portfolio worldwide.  AAC has the global licensing rights for the portfolio, including its Vision AI platform and its versatile retinal cameras.

Avant and Ainnova have identified Brazil and the United States as key strategic markets.  Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.  

At the same time, Ainnova is advancing its regulatory roadmap for the U. S.  The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc. 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai 
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact: 
Avant Technologies, Inc. info@avanttechnologies.com

Logo - https://mma.prnewswire.com/media/2370694/5271367/Avant_Technologies.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-jv-partner-ainnova-accelerate-expansion-across-latin-america-following-key-role-at-healthcare-innovation-summit-302430278.html

SOURCE Avant Technologies Inc.

FAQ

What is the purpose of Avant Technologies (AVAI) and Ainnova's commercial pilots in Latin America?

The pilots aim to demonstrate cost reduction in preventive diagnostics, increased medical resource efficiency, enhanced institutional reputation, and improved profitability through optimized patient referrals.

What health conditions can Ainnova's Vision AI platform detect through retinal screening?

The platform screens for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data.

What are AVAI's expansion plans for Brazil and the United States in 2025?

The company is pursuing ANVISA approval in Brazil through MDSAP certification and planning FDA clinical trials in the US, targeting markets with existing diabetic retinopathy reimbursement codes.

What technology rights does Ai-nova Acquisition Corp (AAC) hold from the AVAI-Ainnova partnership?

AAC holds global licensing rights for Ainnova's entire technology portfolio, including the Vision AI platform and versatile retinal cameras.